The stock of ChemoCentryx, Inc. (NASDAQ:CCXI) hit a new 52-week high and has $15.59 target or 7.00% above today’s $14.57 share price. The 6 months bullish chart indicates low risk for the $765.94 million company. The 1-year high was reported on Apr, 3 by Barchart.com. If the $15.59 price target is reached, the company will be worth $53.62 million more. The stock increased 3.48% or $0.49 during the last trading session, reaching $14.57. About 261,578 shares traded. ChemoCentryx, Inc. (NASDAQ:CCXI) has risen 12.22% since April 3, 2018 and is uptrending. It has outperformed by 7.85% the S&P500. Some Historical CCXI News: 09/03/2018 – CCXI PLANS TO START DEVT AVACOPAN IN HIDRADENITIS SUPPURATIVA; 22/03/2018 – ChemoCentryx Publishes Novel Findings of Role of CCR2 in Kidney Glomerulus, Supporting Advancement of CCR2 Inhibitor CCX140 in the Treatment of Focal Segmental Glomerulosclerosis (FSGS); 11/04/2018 – ChemoCentryx Announces Presentation During National Kidney Foundation 2018 Spring Clinical Meeting; 09/03/2018 – CHEMOCENTRYX INC QUARTERLY SHR $0.80; 22/03/2018 – ChemoCentryx Publishes Novel Findings of Role of CCR2 in Kidney Glomerulus, Supporting Advancement of CCR2 Inhibitor CCX140 in; 09/03/2018 – CCXI TO BEGIN AVACOPAN CLINICAL STUDIES IN HS BY ’18 END; 09/03/2018 – ChemoCentryx Intends to Initiate Clinical Development of Avacopan in Hidradenitis Suppurativa by Yr-En; 03/04/2018 – ChemoCentryx Presenting at Conference Apr 9; 09/03/2018 – CHEMOCENTRYX SEES 2018 CASH & INVESTMENTS USE $65M-$75M; 09/03/2018 – ChemoCentryx Expects to Utilize Between $65M-$75M Cash and Investments in FY18
Cibc Asset Management Inc increased Maxim Integrated Prods Inc (MXIM) stake by 56.53% reported in 2018Q4 SEC filing. Cibc Asset Management Inc acquired 14,465 shares as Maxim Integrated Prods Inc (MXIM)’s stock declined 1.53%. The Cibc Asset Management Inc holds 40,055 shares with $2.04 million value, up from 25,590 last quarter. Maxim Integrated Prods Inc now has $15.64B valuation. The stock increased 4.08% or $2.24 during the last trading session, reaching $57.2. About 1.70 million shares traded. Maxim Integrated Products, Inc. (NASDAQ:MXIM) has declined 9.10% since April 3, 2018 and is downtrending. It has underperformed by 13.47% the S&P500. Some Historical MXIM News: 23/05/2018 – Maxim’s Compact Synchronous Buck Converters Provide Industry’s Lowest EMI Performance for Automotive lnfotainment and ADAS Applications; 26/04/2018 – Maxim Integrated Sees 4Q Rev $610M-$650M; 09/04/2018 – Reed’s Non-Deal Roadshow Scheduled By Maxim for Apr. 16; 07/03/2018 – Control4 Non-Deal Roadshow Scheduled By Maxim for Mar. 14-15; 12/04/2018 – Profire Energy at Non-Deal Roadshow Hosted By Maxim Today; 26/04/2018 – MAXIM INTEGRATED PRODUCTS INC – SEES FOR JUNE 2018 QUARTER EPS $0.62 TO $0.68 GAAP; 20/03/2018 – Gil Sharon-Maxim Group Stockbroker-Discloses Customer Disputes-Cleveland, OH; 08/05/2018 – MAXIM POWER CORP – AS PREVIOUSLY REPORTED, MAXIM INTENDS TO RESUME OPERATIONS OF MILNER IN MID-2018; 15/03/2018 – MAXIM POWER CORP – PLANT STAFF LEVELS HAVE BEEN REDUCED BY 88% THROUGH TEMPORARY LAYOFFS WHILE OPERATIONS ARE SUSPENDED; 19/03/2018 – AIRBORNE WIRELESS SAYS MAXIM GROUP TO BE UNDERWRITER IN IPO
More notable recent Maxim Integrated Products, Inc. (NASDAQ:MXIM) news were published by: Nasdaq.com which released: “Cirrus Logic Not in Apple’s Latest AirPods? Relax. – Nasdaq” on April 02, 2019, also Nasdaq.com with their article: “MXIM Makes Bullish Cross Above Critical Moving Average – Nasdaq” published on April 03, 2019, Seekingalpha.com published: “Cirrus Logic drops on AirPods exclusion – Craig-Hallum – Seeking Alpha” on April 01, 2019. More interesting news about Maxim Integrated Products, Inc. (NASDAQ:MXIM) were released by: Prnewswire.com and their article: “Maxim Unveils Smallest, Most Power-Efficient Dual IO-Link Transceiver with DC-DC Regulator and Surge Protection – PRNewswire” published on April 02, 2019 as well as Bizjournals.com‘s news article titled: “Cincinnati firm forms collaboration with major player in Silicon Valley – Cincinnati Business Courier” with publication date: April 01, 2019.
Among 8 analysts covering Maxim Integrated Products (NASDAQ:MXIM), 2 have Buy rating, 1 Sell and 5 Hold. Therefore 25% are positive. Maxim Integrated Products had 10 analyst reports since October 18, 2018 according to SRatingsIntel. The firm has “Buy” rating by Jefferies given on Wednesday, October 31. The firm has “Equal-Weight” rating by Barclays Capital given on Tuesday, October 23. The rating was maintained by Morgan Stanley with “Equal-Weight” on Wednesday, December 19. The firm earned “Neutral” rating on Wednesday, October 31 by Citigroup. Morgan Stanley maintained Maxim Integrated Products, Inc. (NASDAQ:MXIM) rating on Wednesday, October 31. Morgan Stanley has “Equal-Weight” rating and $54 target. On Thursday, February 21 the stock rating was initiated by Cowen & Co with “Hold”. Deutsche Bank maintained the shares of MXIM in report on Wednesday, October 31 with “Buy” rating. The stock of Maxim Integrated Products, Inc. (NASDAQ:MXIM) has “Neutral” rating given on Friday, January 4 by Bank of America. The company was downgraded on Thursday, October 18 by Goldman Sachs.
Investors sentiment decreased to 0.89 in Q4 2018. Its down 0.42, from 1.31 in 2018Q3. It fall, as 65 investors sold MXIM shares while 148 reduced holdings. 65 funds opened positions while 124 raised stakes. 265.84 million shares or 7.59% more from 247.08 million shares in 2018Q3 were reported. Barclays Public Llc accumulated 450,193 shares or 0.02% of the stock. Boston Private Wealth reported 50,433 shares stake. Ancora Advsrs Ltd Liability Corporation accumulated 0.01% or 5,740 shares. Cambridge Inv Rech Advsrs Inc holds 0.01% of its portfolio in Maxim Integrated Products, Inc. (NASDAQ:MXIM) for 18,332 shares. Brinker Capital stated it has 25,710 shares or 0.06% of all its holdings. Federated Investors Inc Pa has 3,170 shares. First Trust Advsrs LP reported 1.26M shares. Cibc Asset owns 40,055 shares. Hamilton Point Inv Advsr Ltd Liability Corp reported 38,493 shares. Willingdon Wealth has 0.24% invested in Maxim Integrated Products, Inc. (NASDAQ:MXIM) for 16,050 shares. Moreover, Utah Retirement Systems has 0.06% invested in Maxim Integrated Products, Inc. (NASDAQ:MXIM) for 51,857 shares. Strategy Asset Managers Limited reported 127,709 shares. 23,391 are owned by Los Angeles Capital Mngmt & Equity Rech. Wells Fargo Mn has invested 0.12% in Maxim Integrated Products, Inc. (NASDAQ:MXIM). Moreover, Cwm Ltd Liability has 0% invested in Maxim Integrated Products, Inc. (NASDAQ:MXIM).
Cibc Asset Management Inc decreased Stryker Corp (NYSE:SYK) stake by 4,679 shares to 40,635 valued at $6.37M in 2018Q4. It also reduced Telus Corp (NYSE:TU) stake by 652,654 shares and now owns 11.73 million shares. Ishares Inc was reduced too.
Since November 16, 2018, it had 0 insider buys, and 12 sales for $3.90 million activity. On Thursday, December 13 the insider Preeshl Bryan sold $49,573. Wright Mary Ann sold $23,034 worth of stock. $234,248 worth of Maxim Integrated Products, Inc. (NASDAQ:MXIM) was sold by BERGMAN JAMES R on Friday, November 16. On Monday, December 3 DOLUCA TUNC sold $427,375 worth of Maxim Integrated Products, Inc. (NASDAQ:MXIM) or 7,500 shares. On Monday, December 3 the insider KIDDOO BRUCE E sold $1.41M. 5,000 Maxim Integrated Products, Inc. (NASDAQ:MXIM) shares with value of $273,369 were sold by BRONSON JOSEPH R. Another trade for 2,830 shares valued at $153,517 was made by Accardi Tracy on Wednesday, December 12.
Among 5 analysts covering ChemoCentryx (NASDAQ:CCXI), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. ChemoCentryx had 5 analyst reports since November 12, 2018 according to SRatingsIntel. On Thursday, February 14 the stock rating was initiated by Leerink Swann with “Buy”. The firm has “Buy” rating by H.C. Wainwright given on Tuesday, March 12. The company was maintained on Monday, November 12 by Canaccord Genuity. The stock of ChemoCentryx, Inc. (NASDAQ:CCXI) earned “Buy” rating by FBR Capital on Wednesday, March 27.
Investors sentiment decreased to 0.93 in Q4 2018. Its down 0.05, from 0.98 in 2018Q3. It turned negative, as 7 investors sold ChemoCentryx, Inc. shares while 38 reduced holdings. 18 funds opened positions while 24 raised stakes. 27.13 million shares or 1.23% more from 26.80 million shares in 2018Q3 were reported. Sectoral Asset Mngmt stated it has 17,811 shares or 0.03% of all its holdings. Clarivest Asset Management Limited Liability Company owns 48,300 shares for 0.01% of their portfolio. 25,400 are held by Ny State Common Retirement Fund. Bvf Inc Il reported 9.54% in ChemoCentryx, Inc. (NASDAQ:CCXI). Wasatch Advisors Inc invested in 0.34% or 2.32M shares. State Street Corp reported 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). Sio Mgmt Lc owns 169,257 shares. Arrowstreet Partnership invested 0.01% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI). Cadence Capital Mgmt holds 103,341 shares. Alps Advsr has invested 0.01% in ChemoCentryx, Inc. (NASDAQ:CCXI). J Goldman Ltd Partnership has invested 0.04% in ChemoCentryx, Inc. (NASDAQ:CCXI). Bank Of Montreal Can owns 0% invested in ChemoCentryx, Inc. (NASDAQ:CCXI) for 129,083 shares. Strs Ohio accumulated 55,800 shares. Franklin holds 0.01% or 1.38 million shares in its portfolio. 81,534 were reported by Matarin Cap Mgmt Ltd Liability Com.
ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. The company has market cap of $765.94 million. The Company’s lead drug candidate is Avacopan , an orally-administered small molecule that is a selective inhibitor of the complement C5a receptor (C5Ar), which is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV). It currently has negative earnings. The firm also engages in developing CCX140, an inhibitor of the chemokine receptor known as CCR2 for patients with focal segmental glomerulosclerosis (FSGS), a debilitating kidney disease; Vercirnon for the treatment of patients with moderate-to-severe CrohnÂ’s diseases; CCX872, a selective inhibitor of the human CCR2 that has completed Phase I clinical trial for the treatment of pancreatic cancer; CCX507, which has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and Th17 cells for the treatment of psoriasis, rheumatoid arthritis, asthma, and multiple sclerosis.
More notable recent ChemoCentryx, Inc. (NASDAQ:CCXI) news were published by: Globenewswire.com which released: “ChemoCentryx Appoints Rita Jain, M.D. to Board of Directors – GlobeNewswire” on March 28, 2019, also Seekingalpha.com with their article: “ChemoCentryx, Inc. (CCXI) CEO Thomas Schall on Q4 2018 Results – Earnings Call Transcript – Seeking Alpha” published on March 12, 2019, Nasdaq.com published: “ChemoCentryx (CCXI) Looks Good: Stock Adds 5.5% in Session – Nasdaq” on March 19, 2019. More interesting news about ChemoCentryx, Inc. (NASDAQ:CCXI) were released by: Nasdaq.com and their article: “ChemoCentryx (CCXI) Reports Q4 Loss, Lags Revenue Estimates – Nasdaq” published on March 11, 2019 as well as Nasdaq.com‘s news article titled: “After-Hours Earnings Report for March 11, 2019 : ADT, COUP, SFIX, DRNA, AVD, PETQ, CCXI, LXFR, MG, OXFD, FRTA, KALA – Nasdaq” with publication date: March 11, 2019.